Antibody Therapies for Overdose Reversal
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
32
NCT06005402
Safety, Tolerability, and Pharmacokinetics of CSX-1004
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 1, 2023
Completion: May 28, 2024
Loading map...